BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34954051)

  • 1. Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review.
    O'Shea JP; Augustijns P; Brandl M; Brayden DJ; Brouwers J; Griffin BT; Holm R; Jacobsen AC; Lennernäs H; Vinarov Z; O'Driscoll CM
    Eur J Pharm Sci; 2022 Mar; 170():106098. PubMed ID: 34954051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective.
    Wilson CG; Aarons L; Augustijns P; Brouwers J; Darwich AS; De Waal T; Garbacz G; Hansmann S; Hoc D; Ivanova A; Koziolek M; Reppas C; Schick P; Vertzoni M; García-Horsman JA
    Eur J Pharm Sci; 2022 May; 172():106100. PubMed ID: 34936937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs.
    Bergström CA; Holm R; Jørgensen SA; Andersson SB; Artursson P; Beato S; Borde A; Box K; Brewster M; Dressman J; Feng KI; Halbert G; Kostewicz E; McAllister M; Muenster U; Thinnes J; Taylor R; Mullertz A
    Eur J Pharm Sci; 2014 Jun; 57():173-99. PubMed ID: 24215735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products - a PEARRL review.
    Guimarães M; Statelova M; Holm R; Reppas C; Symilllides M; Vertzoni M; Fotaki N
    J Pharm Pharmacol; 2019 Apr; 71(4):603-642. PubMed ID: 29971768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Predictive Dissolution (IPD) and Biopharmaceutical Modeling and Simulation: Future Use of Modern Approaches and Methodologies in a Regulatory Context.
    Lennernäs H; Lindahl A; Van Peer A; Ollier C; Flanagan T; Lionberger R; Nordmark A; Yamashita S; Yu L; Amidon GL; Fischer V; Sjögren E; Zane P; McAllister M; Abrahamsson B
    Mol Pharm; 2017 Apr; 14(4):1307-1314. PubMed ID: 28195732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development.
    Lennernäs H
    Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans.
    Lennernäs H
    Curr Drug Metab; 2007 Oct; 8(7):645-57. PubMed ID: 17979653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project.
    Abrahamsson B; McAllister M; Augustijns P; Zane P; Butler J; Holm R; Langguth P; Lindahl A; Müllertz A; Pepin X; Rostami-Hodjegan A; Sjögren E; Berntsson M; Lennernäs H
    Eur J Pharm Biopharm; 2020 Jul; 152():236-247. PubMed ID: 32446960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based biopharmaceutics modeling of regional and colon absorption in humans.
    Tannergren C; Jadhav H; Eckernäs E; Fagerberg J; Augustijns P; Sjögren E
    Eur J Pharm Biopharm; 2023 May; 186():144-159. PubMed ID: 37028605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A reaction limited in vivo dissolution model for the study of drug absorption: Towards a new paradigm for the biopharmaceutic classification of drugs.
    Macheras P; Iliadis A; Melagraki G
    Eur J Pharm Sci; 2018 May; 117():98-106. PubMed ID: 29425862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
    Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
    Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.